Phase IPeptide
Compound 61446
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061446
Risk Class
MODERATE
Last Audit
Feb 13, 2108
Research Abstract
Peptide candidate engineered for cognitive resilience initiatives with automated dossier coverage.
Compound 61446 is a peptide asset inside peptide innovation track initiatives, optimized for cognitive resilience and neuroprotection.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061446 with updates logged 2108-02-13.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cognitive resilienceNeuroprotection
Nomenclature
CX-61446Peptide Program 61446
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061446
- [2] Operations Pulse • Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61446